Baird Financial Group Inc. Sells 125,438 Shares of Boston Scientific Corporation $BSX

Key Points

• Baird Financial Group cut its Boston Scientific stake by 72.8% in the second quarter, selling 125,438 shares and retaining 46,812 shares valued at approximately $2.0 million. Institutional investors collectively own 89.07% of the company.
• Boston Scientific exceeded quarterly expectations, reporting $0.86 in adjusted EPS versus an $0.83 consensus estimate and $5.44 billion in revenue, up 7.5% year over year. The company forecast third-quarter 2026 EPS of $0.80–$0.82 and full-year EPS of $3.28–$3.32.
• Analyst sentiment remains broadly positive, with a consensus “Moderate Buy” rating and a $71.04 price target, despite recent target reductions. Insiders also purchased 194,522 shares worth about $9.4 million over the past three months.

Baird Financial Group Inc. lessened its position in Boston Scientific Corporation (NYSE:BSX - Free Report) by 72.8% in the second quarter, according to its most recent disclosure with the SEC. The firm owned 46,812 shares of the medical equipment provider's stock after selling 125,438 shares during the period. Baird Financial Group Inc.'s holdings in Boston Scientific were worth $1,998,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also recently modified their holdings of the company. South Plains Financial Inc. bought a new stake in shares of Boston Scientific during the fourth quarter worth about $39,000. Clal Insurance Enterprises Holdings Ltd bought a new position in Boston Scientific in the 1st quarter valued at about $28,000. Cassaday & Co Wealth Management LLC acquired a new position in Boston Scientific during the 1st quarter valued at about $32,000. Measured Wealth Private Client Group LLC boosted its stake in Boston Scientific by 244.9% during the 1st quarter. Measured Wealth Private Client Group LLC now owns 545 shares of the medical equipment provider's stock valued at $34,000 after purchasing an additional 387 shares during the last quarter. Finally, Murphy & Mullick Capital Management Corp increased its holdings in Boston Scientific by 121.6% during the 4th quarter. Murphy & Mullick Capital Management Corp now owns 565 shares of the medical equipment provider's stock worth $54,000 after purchasing an additional 310 shares in the last quarter. Institutional investors own 89.07% of the company's stock.

Boston Scientific Stock Performance

Shares of BSX opened at $43.56 on Friday. The stock has a 50 day moving average of $46.93 and a 200 day moving average of $53.64. The company has a market capitalization of $63.13 billion, a price-to-earnings ratio of 17.64, a PEG ratio of 1.02 and a beta of 0.57. Boston Scientific Corporation has a 12 month low of $42.20 and a 12 month high of $105.65. The company has a current ratio of 1.24, a quick ratio of 0.74 and a debt-to-equity ratio of 0.43.

Boston Scientific (NYSE:BSX - Get Free Report) last posted its quarterly earnings data on Wednesday, July 29th. The medical equipment provider reported $0.86 earnings per share for the quarter, topping the consensus estimate of $0.83 by $0.03. The business had revenue of $5.44 billion for the quarter, compared to analysts' expectations of $5.38 billion. Boston Scientific had a return on equity of 19.28% and a net margin of 17.50%.The business's revenue was up 7.5% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.75 earnings per share. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. As a group, sell-side analysts forecast that Boston Scientific Corporation will post 3.29 earnings per share for the current year.

Analyst Ratings Changes

A number of research analysts have recently weighed in on BSX shares. Stifel Nicolaus set a $60.00 target price on Boston Scientific in a report on Wednesday, July 29th. BTIG Research decreased their price target on Boston Scientific from $60.00 to $56.00 and set a "buy" rating for the company in a report on Wednesday, September 9th. Raymond James Financial reissued an "outperform" rating and issued a $57.00 price target on shares of Boston Scientific in a research report on Thursday, July 30th. Jefferies Financial Group dropped their price objective on Boston Scientific from $100.00 to $67.00 and set a "buy" rating on the stock in a research note on Wednesday, June 24th. Finally, Weiss Ratings lowered shares of Boston Scientific from a "hold (c-)" rating to a "sell (d+)" rating in a research note on Tuesday, July 7th. Twenty-three research analysts have rated the stock with a Buy rating, six have assigned a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat.com, Boston Scientific presently has a consensus rating of "Moderate Buy" and a consensus price target of $71.04.

Insider Buying and Selling at Boston Scientific

In other news, CEO Michael F. Mahoney acquired 186,240 shares of Boston Scientific stock in a transaction on Monday, August 3rd. The stock was acquired at an average cost of $48.33 per share, with a total value of $9,000,979.20. Following the completion of the acquisition, the chief executive officer owned 1,590,024 shares in the company, valued at approximately $76,845,859.92. This trade represents a 13.27% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Edward J. Ludwig bought 5,000 shares of the firm's stock in a transaction on Friday, July 31st. The stock was purchased at an average cost of $45.48 per share, with a total value of $227,400.00. Following the completion of the transaction, the director directly owned 30,359 shares of the company's stock, valued at approximately $1,380,727.32. The trade was a 19.72% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Insiders have purchased a total of 194,522 shares of company stock worth $9,385,210 over the last three months. 0.34% of the stock is currently owned by insiders.

Boston Scientific Company Profile

Boston Scientific Corporation is a medical device company that develops, manufactures and markets products used in minimally invasive procedures. Its technologies are designed to diagnose and treat a range of medical conditions while supporting less invasive alternatives to traditional surgery.

The company's products address cardiovascular, endoscopy, urology, pelvic health and neuromodulation applications. Its portfolio includes devices used in cardiac rhythm management and electrophysiology, structural heart procedures, peripheral and vascular interventions, gastrointestinal procedures, kidney stone and prostate treatments, and therapies for chronic pain and other neurological conditions.

Founded in 1979, Boston Scientific serves healthcare providers and patients in markets around the world.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.